| Literature DB >> 23416208 |
Arturo Galindo-Fraga1, Ana A Ortiz-Hernández, Alejandra Ramírez-Venegas, Rafael Valdez Vázquez, Sarbelio Moreno-Espinosa, Beatriz Llamosas-Gallardo, Santiago Pérez-Patrigeon, Maggie Salinger, Laura Freimanis, Chiung-yu Huang, Wenjuan Gu, M Lourdes Guerrero, John Beigel, Guillermo M Ruiz-Palacios.
Abstract
BACKGROUND: Influenza-like illnesses (ILI) are estimated to cause millions of deaths annually. Despite this disease burden, the etiologic causes of ILI are poorly described for many geographical regions.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23416208 PMCID: PMC3655081 DOI: 10.1016/j.ijid.2013.01.006
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Figure 1Enrollment and follow-up.
Baseline characteristics
| Demographics | Total, | Children, | Adults, |
|---|---|---|---|
| Age, years | |||
| Median | 33 | ||
| Range | 0–96 | ||
| ≤18 | 262 (24.6%) | ||
| 19–59 | 614 (57.6%) | ||
| ≥60 | 189 (17.8%) | ||
| Sex | |||
| Male | 439 (41.2%) | 132 (50.4%) | 307 (38.2%) |
| Female | 626 (58.8%) | 130 (49.6%) | 496 (61.8%) |
| Pregnant | 4 | 4 | |
| Ethnicity | |||
| Mixed | 1026 (96.4%) | 252 (96.2%) | 775 (96.5%) |
| White | 33 (3.1%) | 10 (3.8%) | 23 (2.9%) |
| Other | 5 (0.5%) | 5 (0.6%) | |
| Medical history | |||
| Influenza vaccination | 504 (47.3%) | 121 (46.2%) | 383 (47.7%) |
| Asthma | 151 (14.2%) | 16 (6.1%) | 135 (16.8%) |
| CVD | 147 (13.8%) | 17 (6.5%) | 130 (16.2%) |
| Diabetes | 99 (9.3%) | 99 (12.3%) | |
| Immunodeficiency | 48 (4.5%) | 8 (3.1%) | 40 (5.0%) |
| Renal disorder | 42 (3.9%) | 4 (1.5%) | 38 (4.8%) |
| COPD | 36 (3.4%) | 36 (4.5%) | |
| BMI category | |||
| Obese | 207 (19.9%) | 23 (9.2%) | 184 (23.3%) |
| Overweight | 313 (30.2%) | 42 (16.1%) | 273 (34.6%) |
| Normal | 417 (40.2%) | 121 (48.6%) | 296 (37.5%) |
| Underweight | 101 (9.7%) | 65 (26.1%) | 36 (4.6%) |
| Median days since symptoms onset | 1 | ||
| Inpatient at baseline | 436 (40.9%) | 113 (43.1%) | 323 (40.2%) |
| Outpatient at baseline | 629 (59.1%) | 149 (56.9%) | 480 (59.8) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; SD, standard deviation.
BMI categories: underweight = BMI < 18.5 kg/m2 (or <1 SD for children); normal weight = 18.5–24.9 kg/m2; overweight = 25–29.9 kg/m2 (>1SD for children); obese = BMI of ≥30 kg/m2 (>2 SD for children).
Frequency distribution of viral isolates
| Pathogen | Age <18 | Age 18–59 | Age ≥60 | Total | Total |
|---|---|---|---|---|---|
| Adenovirus | 17 (6.6) | 15 (2.5) | 3 (1.6) | 35 (3.3) | 74 (9.0) |
| 2 (0.8) | 3 (0.5) | 0 (0) | 5 (0.5) | 9 (1.1) | |
| Coronavirus | 12 (4.7) | 50 (8.2) | 15 (8.2) | 77 (7.3) | 118 (14.4) |
| 229E | 0 | 11 | 2 | 13 | 22 |
| NL63 | 2 | 8 | 1 | 11 | 18 |
| OC43 | 10 | 31 | 12 | 53 | 78 |
| Influenza | 43 (16.7) | 89 (14.6) | 18 (9.8) | 150 (14.3) | 197 (24.0) |
| A | 3 | 5 | 0 | 8 | 11 |
| A H1N1 2009 | 0 | 5 | 1 | 6 | 7 |
| A H3N2 | 16 | 46 | 11 | 73 | 91 |
| B | 24 | 33 | 6 | 63 | 88 |
| Metapneumovirus | 11 (4.3) | 22 (3.6) | 9 (4.9) | 42 (4.0) | 78 (9.5) |
| 1 (0.4) | 4 (0.7) | 1 (0.5) | 6 (0.6) | 10 (1.2) | |
| Parainfluenza virus | 6 (2.3) | 12 (1.9) | 2 (1.1) | 20 (1.9) | 42 (5.1) |
| 1 | 0 | 0 | 0 | 0 | 3 |
| 2 | 0 | 0 | 0 | 0 | 3 |
| 3 | 6 | 7 | 1 | 14 | 24 |
| 4 | 0 | 5 | 1 | 6 | 12 |
| Rhinovirus | 29 (11.2) | 100 (16.4) | 32 (17.4) | 161 (15.3) | 208 (25.3) |
| RSV | 34 (13.2) | 15 (2.5) | 8 (4.3) | 57 (5.4) | 85 (10.3) |
| A | 33 | 15 | 6 | 54 | 72 |
| B | 1 | 0 | 2 | 3 | 13 |
| Mixed infections | 51 (19.8) | 60 (9.9) | 14 (7.6) | 125 (11.9) | |
| Negative cases | 52 (20.2) | 238 (39.1) | 83 (45.1) | 373 (35.5) | |
| Total | 258 (100) | 609 (100) | 184 (100) | 1051 (100) | 821 (100) |
RSV, respiratory syncytial virus.
Frequency by subject. Infections with more than one virus are counted as a single category (mixed infection).
Frequency by isolates. Excludes negative cases.
Fourteen subjects did not have a baseline sample for virologic testing.
Figure 2Monthly distribution of viral isolates. Total monthly enrollment (line), and the four most prevalent viruses (A). Monthly isolates by virus subtype (bars) and percent positive are demonstrated for the five most common viruses: influenza (B), coronavirus (C), respiratory syncytial virus (D), metapneumovirus (E), and rhinovirus (F).
Demographics and symptoms by age and pathogen
| Children | Adults | |||||||
|---|---|---|---|---|---|---|---|---|
| Coronavirus | Influenza | Rhinovirus | RSV | Coronavirus | Influenza | Rhinovirus | RSV | |
| Number enrolled | 12 | 43 | 29 | 34 | 65 | 107 | 132 | 23 |
| Any antiviral | 0% | 9% | 7% | 6% | 28% | 33% | 27% | 35% |
| Chronic medical condition | 42% | 28% | 38% | 26% | 42% | 44% | 63% | 74% |
| Asthma | 8% | 7% | 10% | 3% | 11% | 21% | 19% | 26% |
| CVD | 0% | 0% | 10% | 6% | 15% | 10% | 20% | 17% |
| COPD | 0% | 0% | 0% | 0% | 5% | 6% | 2% | 13% |
| DM | 0% | 0% | 0% | 0% | 8% | 6% | 19% | 13% |
| Antibiotics | 50% | 44% | 52% | 71% | 40% | 48% | 66% | 65% |
| Inhaled steroids | 8% | 9% | 21% | 24% | 18% | 20% | 14% | 35% |
| Systemic steroids | 25% | 9% | 17% | 21% | 22% | 24% | 28% | 43% |
| Pregnant | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 0% |
| Non-smoker | 0% | 0% | 0% | 0% | 72% | 51% | 60% | 65% |
| Current/former smoker | 0% | 0% | 0% | 0% | 28% | 49% | 40% | 35% |
| Seasonal flu vaccine | 50% | 47% | 45% | 38% | 60% | 39% | 39% | 52% |
| Outpatient | 67% | 81% | 38% | 35% | 68% | 67% | 52% | 57% |
| Hospitalized | 33% | 19% | 62% | 65% | 32% | 33% | 48% | 43% |
| Symptoms | ||||||||
| Rales/crepitations | 33% | 16% | 55% | 79% | 25% | 29% | 39% | 26% |
| Wheezing | 25% | 16% | 21% | 29% | 12% | 22% | 25% | 35% |
| Fever | 67% | 95% | 69% | 100% | 45% | 79% | 65% | 70% |
| Productive cough | 75% | 65% | 83% | 88% | 52% | 59% | 58% | 57% |
| Diarrhea | 0% | 9% | 0% | 12% | 6% | 11% | 4% | 4% |
| Dyspnea | 0% | 16% | 31% | 38% | 22% | 33% | 39% | 43% |
| Fatigue | 0% | 58% | 34% | 32% | 71% | 64% | 41% | 57% |
| Headache | 0% | 51% | 21% | 12% | 74% | 75% | 55% | 39% |
| Nausea | 17% | 42% | 14% | 24% | 15% | 21% | 9% | 22% |
| Red eyes | 0% | 49% | 17% | 9% | 37% | 27% | 13% | 17% |
| Sore throat | 25% | 60% | 14% | 15% | 65% | 61% | 47% | 52% |
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; RSV, respiratory syncytial virus.
Hospitalizations and deaths by pathogen
| Pathogen | Hospitalized % ( | Death % ( | ||||
|---|---|---|---|---|---|---|
| Age <18 | Age 18–59 | Age ≥60 | Age <18 | Age 18–59 | Age ≥60 | |
| Adenovirus | 41.8% (7) | 66.7% (10) | 100% (3) | 6.7% (1) | ||
| 100% (2) | 33.3% (1) | |||||
| Coronavirus | 33.3% (4) | 24% (12) | 73.3% (11) | 2% (1) | 13.3% (2) | |
| 229E | 45.5% (5) | 100% (2) | ||||
| NL63 | 25% (2) | 100% (1) | ||||
| OC43 | 40% (4) | 16.1% (5) | 66.7% (8) | 3.2% (1) | 16.7% (2) | |
| Influenza | 25.6% (11) | 43.8% (39) | 72.2% (13) | 11.1% (2) | ||
| A | 60% (3) | |||||
| A H1N1 2009 | 80% (4) | |||||
| A H3N2 | 25% (4) | 50% (23) | 72.7% (8) | 9.1% (1) | ||
| B | 29.2% (7) | 27.3% (9) | 83.3% (5) | 16.7% (1) | ||
| Metapneumovirus | 63.6% (7) | 50% (11) | 88.9% (8) | 22.2% (2) | ||
| 100% (4) | 100% (1) | 100% (1) | ||||
| Parainfluenza virus | 66.7% (4) | 41.7% (5) | 100% (2) | 16.7% (1) | ||
| 1 | ||||||
| 2 | ||||||
| 3 | 66.7% (4) | 42.9% (3) | 100% (1) | 16.7% (1) | ||
| 4 | 40% (2) | 100% (1) | ||||
| Rhinovirus | 58.6% (17) | 59% (59) | 81.3% (26) | 7% (7) | 12.5% (4) | |
| Respiratory syncytial virus | 76.5% (26) | 53.3% (8) | 100% (8) | 5.9% (2) | 25% (2) | |
| A | 75.8% (25) | 53.3% (8) | 100% (6) | 6.1% (2) | 33.3% (2) | |
| B | 100% (1) | 100% (2) | ||||
| Mixed infections | 49% (25) | 56.7% (34) | 100% (14) | 10% (6) | 7.1% (1) | |
| Negative cases | 34.6% (18) | 51.7% (123) | 88% (73) | 4.6% (11) | 27.7% (23) | |
| Total | 46.2% (121) | 49.8% (306) | 84.1% (159) | 1.5% (4) | 4.2% (26) | 19% (36) |
Outcomes
| Variable at baseline | Patients who survived | Patients who died | Odds ratio | |
|---|---|---|---|---|
| Median (range), | Median (range), | Estimate (95% CI) | ||
| Creatinine phosphokinase (U/l) | 95 (9–7160) | 90.5 (10–1840) | 1.04 (1.00, 1.08) | 0.066 |
| Creatinine (mg/dl) | 0.6 (0–14) | 1.1 (0.1–9.7) | 1.37 (1.19, 1.58) | <0.001 |
| C-reactive protein (mg/l) | 1.4 (0–36) | 14.25 (1.6–34.1) | 1.12 (1.09, 1.16) | <0.001 |
| Hematocrit (%) | 41.7 (14.3–76.1) | 34.9 (13.2–57.5) | 0.73 (0.66, 0.8) | <0.001 |
| Hemoglobin (g/dl) | 14.1 (4.1–25.4) | 11.7 (4.7–19) | 0.73 (0.66, 0.8) | <0.001 |
| Lactate dehydrogenase (IU/l) | 224 (26–4003) | 338 (31–5175) | 1.19 (1.08, 1.32) | 0.001 |
| Lymph (%) | 18 (0–92) | 7 (1–35) | 0.92 (0.90, 0.95) | <0.001 |
| Lymph absolute (×109/l) | 1.4 (0–35.1) | 0.7 (0.02–6.8) | 0.92 (0.88, 0.95) | <0.001 |
| Neutrophil (%) | 70 (0–97) | 87 (16–98) | 1.06 (1.04, 1.08) | <0.001 |
| Neutrophil absolute (×109/l) | 5.7 (0–26.9) | 8.6 (0.27–27.2) | 1.01 (1.00, 1.01) | 0.001 |
| Platelets (×109/l) | 231 (10–744) | 140 (3–551) | 0.91 (0.88, 0.94) | <0.001 |
| White blood count (×109/l) | 8.5 (0.1–54) | 10.4 (0.3–29.2) | 1.03 (0.99, 1.07) | 0.179 |
CI, confidence interval; COPD, chronic obstructive pulmonary disease.
When analysis for deaths attributed to ILI, the p-value was no longer <0.05.